The short version of certificate of analysis fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-30. Anything still debated is marked as such rather than presented as settled.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
| Property | Value | Notes |
|---|---|---|
| Solubility class | Freely soluble in water | Also soluble in DMSO and some alcohols |
| Typical storage temperature | -20 C or below | Desiccated, protected from light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
| Typical reported purity | 95 percent or higher | Reference-grade material |
| Common synonyms | PT-141 | Also called bremelanotide acetate |
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
== Catalytic mechanism == The accepted catalytic mechanism, called the “ping-pong mechanism,” consists of four major stages. The first stage is the oxidation of the substrate by the double-redox center. After the hydroxyl group of substrate alcohol occupies the solvent coordination site, the hydroxyl group is deprotonated by Tyr495, followed by the release of Tyr495. This step makes the alcohol more prone to oxidation. The proton on the carbon to which the hydroxyl group used to be attached is then transferred to Tyr272 (serving as the hydrogen acceptor), coupled with the oxidation of the substrate. One electron goes to the radical ligand, the other electron goes to the copper(II) center, which is then reduced to copper(I) as a result. Meanwhile, Tyr272 radical is also reduced. The proton subtraction step is rate determining and stereospecific since only the pro-S hydrogen on the alcohol carbon is removed (supported by studies of its kinetic isotope effect). The overall result of stage 1 is the removal of two hydrogen atoms and the removal two electrons from the substrate, of which the order is unclear, however. The second stage is the release of oxidized substrate (aldehyde in this case) and the coordination of dioxygen at the substrate coordination site. In the third stage, dioxygen is rapidly reduced by copper(I) to form superoxide. The superoxide is a reactive species that subtracts the proton and an electron from the Tyr272 and re-forms the tyrosine radical. In the fourth stage, the hydroperoxide deprotonates Tyr496 and is released as H2O2.
Marxism–Leninism has been broadly criticized, particularly in its Stalinist and Maoist variants, across the political spectrum. Most communist states have been regarded as authoritarian, and some of them have been accused of being totalitarian, especially the Soviet Union under Joseph Stalin, China under Mao Zedong, North Korea under Kim Il Sung, and Romania under Nicolae Ceaușescu. Rival ideologies were persecuted, including dissident leftists, and most elections had only one candidate. According to Daniel Gray, Silvio Pons, and David Martin Walker, Marxist–Leninist regimes have carried out killings and political repression of dissidents and social classes ("enemies of the people"), such as the Red Terror and Great Purge in the Soviet Union and the Campaign to Suppress Counterrevolutionaries in China, partly as a result of Marxist–Leninist ideology. According to Gray, they were justified as a means of maintaining "proletarian power". According to Gray and Walker, political dissidents were deemed to be "distorting the true path to communism". According to Pons, repression of social groups was deemed a necessary part of class struggle against the "exploiting classes". In addition, Robert Service stated that mass religious persecution, such as in the Soviet Union and in China, was motivated by Marxist–Leninist atheism.
== Genetics == The gene for renin, REN, spans 12 kb of DNA and contains 8 introns. It produces several mRNA that encode different REN isoforms. Mutations in the REN gene can be inherited, and are a cause of a rare inherited kidney disease, so far found to be present in only 2 families. This disease is autosomal dominant, meaning that it is characterized by a 50% chance of inheritance and is a slowly progressive chronic kidney disease that leads to the need for dialysis or kidney transplantation. Many—but not all—patients and families with this disease have an elevation in serum potassium and unexplained anemia relatively early in life. Patients with a mutation in this gene can have a variable rate of loss of kidney function, with some individuals going on dialysis in their 40s while others may not go on dialysis until into their 70s. This is a rare inherited kidney disease that exists in less than 1% of people with kidney disease.
Sources: en.wikipedia.org
After collection, sperm must be processed for storage. According to the Sperm Bank of California, sperm banks can use the 'unwashed' or 'wash' method to process sperm samples. The 'wash' method includes removing unwanted particles and adding buffer solutions to preserve viable sperm. However, this approach can contribute to further stress on the sperm cells and decrease the survival of sperm after freezing. The 'unwashed' approach allows for more flexibility to freeze the semen sample, and increases the number of sperm that survive. A cryoprotectant semen extender is conducted if the semen sample is placed in a freezer for storage. Semen extenders play a key role in protecting sperm from 'freeze and osmotic shock, oxidative stress, and cell injury' due to the formation of ice crystals during frozen storage. The semen is preserved by stabilizing the properties of the sperm cells such as the membrane, motility, and 'DNA integrity' in order to create a sustainable viable environment. There are two common forms of medium for sperm cyropreservation, one containing egg yolk from hens and glycerol, and the other containing just glycerol. One study in 2009 compared media supplemented with egg yolk and media supplemented with soy lecithin, finding that there was no significance between sperm motility, morphology, chromatin decondensation, or binding between the two, indicating that soy lecithin may be a viable alternative to egg yolk.
Haplotypes including the SNPs g.-786T>C and Glu298Asp and the VNTR in intron 4 affected the susceptibility to hypertension, preeclampsia, and hypertension in diabetic subjects. NOS3 variants may also affect the responses to drugs that affect NO signaling, such as statins, angiotensin-converting enzyme inhibitors (ACEi) and phosphodiesterase type 5 (PDE-5) inhibitors (PDE5i). Statin treatment was more effective in increasing NO bioavailability in subjects carrying the CC genotype for the g.-786T>C polymorphism than in TT carriers. Hypertensive patients carrying the TC/CC genotypes and the C allele for the g.-786T>C polymorphism showed better antihypertensive responses to ACEi enalapril. Likewise, patients with erectile dysfunction carrying the C allele for g.-786T>C polymorphism showed better responses to PDE-5 inhibitor sildenafil. Together, these studies suggest that statins, ACEi and PDE-5 inhibitors may restore an impaired NO production in subjects carrying the variant allele/genotype for g.-786T>C NOS3 polymorphism, thus attenuating the cardiovascular risk. In addition to analysis of genetic polymorphisms individually, haplotypes including the SNPs g.-786T>C and Glu298Asp and the VNTR in intron 4 were shown to affect the responses to sildenafil in patients with erectile dysfunction.
NMR spectroscopy is nucleus specific. Thus, it can distinguish between hydrogen and deuterium. The amide protons in the protein exchange readily with the solvent, and, if the solvent contains a different isotope, typically deuterium, the reaction can be monitored by NMR spectroscopy. How rapidly a given amide exchanges reflects its solvent accessibility. Thus amide exchange rates can give information on which parts of the protein are buried, hydrogen-bonded, etc. A common application is to compare the exchange of a free form versus a complex. The amides that become protected in the complex, are assumed to be in the interaction interface.
Sources: en.wikipedia.org
The peptide is polar and charged, and reversed-phase chromatography with acidic mobile phases resolves it well from related substances. Ultraviolet detection near 214 nm gives adequate sensitivity without derivatisation.
Aqueous solutions are subject to oxidation and hydrolysis, so concentration and pH drift can occur even under refrigeration. Solid, dry material held cold and desiccated degrades far more slowly.
Mass spectrometry separates the parent from analogues that differ by a single modification, such as an amide versus acid terminus. Retention time alone is less reliable because closely related peptides can co-elute.
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.